{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:03:15Z","timestamp":1792292595215,"version":"4.4.0"},"reference-count":13,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2023,4,18]]},"abstract":"<jats:p>Omadacycline is approved in the United States for the treatment of patients with community-acquired bacterial pneumonia or acute bacterial skin and skin structure infections. Analyses were undertaken to evaluate pharmacokinetic differences among subjects or patients stratified by comorbidities.<\/jats:p>","DOI":"10.1128\/aac.02397-21","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T14:11:20Z","timestamp":1678803080000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":6,"title":["Evaluation of the Impact of Comorbidities on Omadacycline Pharmacokinetics"],"prefix":"10.1128","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3468-3343","authenticated-orcid":true,"given":"M.","family":"Trang","sequence":"first","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. A.","family":"Lakota","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0452-682X","authenticated-orcid":true,"given":"M. C.","family":"Safir","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4891-6467","authenticated-orcid":true,"given":"S. M.","family":"Bhavnani","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Friedrich","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. N.","family":"Steenbergen","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. C.","family":"McGovern","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Tzanis","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3172-0847","authenticated-orcid":true,"given":"C. M.","family":"Rubino","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","volume-title":"NUZYRA (omadacycline) package insert.","author":"Paratek Pharmaceuticals, Inc","year":"2021","unstructured":"Paratek Pharmaceuticals, Inc. 2021. NUZYRA (omadacycline) package insert. Paratek Pharmaceuticals, Inc., Boston, MA."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02263-19"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800201"},{"key":"e_1_3_2_5_2","volume-title":"Omadacycline p-toluenesulfonate tablets and injection for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP). Briefing Document for Antimicrobial Drugs Advisory Committee.","author":"Paratek Pharmaceuticals","year":"2018","unstructured":"Paratek Pharmaceuticals. 2018. Omadacycline p-toluenesulfonate tablets and injection for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP). Briefing Document for Antimicrobial Drugs Advisory Committee. Paratek Pharmaceuticals, Inc., Boston, MA. https:\/\/www.fda.gov\/media\/115100\/download."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199701233360402"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.58.5.377"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02201-21"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.4.943-949.2000"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.3109\/9781420017137.013"},{"key":"e_1_3_2_11_2","first-page":"poster Sunday-1","volume-title":"Microbe 2017, New Orleans, LA, 1 to 5 June 2017.","author":"VanScoy BD","year":"2017","unstructured":"VanScoy BD, Lakota EA, Adams J, Bhavnani SM, Newman J, Ambrose PG. 2017. Pharmacokinetics-pharmacodynamics of efficacy for eravacycline against Escherichia coli in an in vitro infection model, poster Sunday-189. In Microbe 2017, New Orleans, LA, 1 to 5 June 2017. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00250-17"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02213-21"},{"key":"e_1_3_2_14_2","first-page":"abstr P1944","volume-title":"Abstracts of the 29th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, the Netherlands, 13 to 16 April 2019.","author":"Bhavnani SM","year":"2019","unstructured":"Bhavnani SM, Hammel JP, Lakota EA, Liolios K, Rubino CM, Steenbergen JN, Friedrich L, Tzanis A, Ambrose PG. 2019. Assessment of pharmacokinetics-pharmacodynamics to support omadacycline dosing regimens for the treatment of patients with acute bacterial skin and skin structure infections, abstr P1944. In Abstracts of the 29th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, the Netherlands, 13 to 16 April 2019. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.02397-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.02397-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T13:06:41Z","timestamp":1681823201000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.02397-21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,18]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4,18]]}},"alternative-id":["10.1128\/aac.02397-21"],"URL":"https:\/\/doi.org\/10.1128\/aac.02397-21","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,18]]},"assertion":[{"value":"2022-01-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02397-21"}}